User menu

Hematological disorders and leukemia in children with Down syndrome.

Bibliographic reference Bruwier, Annelyse ; Chantrain, Christophe F. Hematological disorders and leukemia in children with Down syndrome.. In: European journal of pediatrics, Vol. 171, no.9, p. 1301-7 (2012)
Permanent URL http://hdl.handle.net/2078.1/125251
  1. Brichard B�n�dicte, Vermylen Christiane, De Potter Patrick, Casteels Ingele, Down syndrome: Possible predisposition to retinoblastoma, 10.1002/mpo.10299
  2. Cabelof D. C., Patel H. V., Chen Q., van Remmen H., Matherly L. H., Ge Y., Taub J. W., Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome, 10.1182/blood-2008-11-190330
  3. de Hingh Yvette C.M., van der Vossen Petrus W., Gemen Eugenie F.A., Mulder André B., Hop Wim C.J., Brus Frank, de Vries Esther, Intrinsic Abnormalities of Lymphocyte Counts in Children with Down Syndrome, 10.1016/j.jpeds.2005.07.022
  4. Elagib K. E., RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation, 10.1182/blood-2002-09-2708
  5. Ensor H. M., Schwab C., Russell L. J., Richards S. M., Morrison H., Masic D., Jones L., Kinsey S. E., Vora A. J., Mitchell C. D., Harrison C. J., Moorman A. V., Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial, 10.1182/blood-2010-07-297135
  6. Fonatsch C (2010) The role of chromosome 21 in hematology and oncology. Genes Chromosomes Cancer 49:497–508
  7. Forestier E., Izraeli S., Beverloo B., Haas O., Pession A., Michalova K., Stark B., Harrison C. J., Teigler-Schlegel A., Johansson B., Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study, 10.1182/blood-2007-09-114231
  8. Gaikwad Amos, Rye Cassia L., Devidas Meenakshi, Heerema Nyla A., Carroll Andrew J., Izraeli Shai, Plon Sharon E., Basso Giuseppe, Pession Andrea, Rabin Karen R., Prevalence and clinical correlates ofJAK2mutations in Down syndrome acute lymphoblastic leukaemia, 10.1111/j.1365-2141.2008.07552.x
  9. Hasle Henrik, Pattern of malignant disorders in individuals with Down's syndrome, 10.1016/s1470-2045(00)00435-6
  10. Hasle H, Niemeyer C M, Chessells J M, Baumann I, Bennett J M, Kerndrup G, Head D R, A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases, 10.1038/sj.leu.2402765
  11. Hastings C, Whithlock JA, La MK, and Seibel N (2007) Improved outcome of children with Down syndrome (DS) and high risk acute lymphocytic leukemia (HR-ALL): a report of CCG-1961. Blood 110:Abstract 586
  12. Henry E., Walker D., Wiedmeier S.E., Christensen R.D., Hematological abnormalities during the first week of life among neonates with Down syndrome: Data from a multihospital healthcare system, 10.1002/ajmg.a.31442
  13. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., Shiloh R., Iacobucci I., Shochat C., Zeligson S., Cario G., Stanulla M., Strehl S., Russell L. J., Harrison C. J., Bornhauser B., Yoda A., Rechavi G., Bercovich D., Borkhardt A., Kempski H., te Kronnie G., Bourquin J.-P., Domany E., Izraeli S., Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group, 10.1182/blood-2009-08-235408
  14. Izraeli S (2010) The acute lymphoblastic leukemias of Down syndrome. 42nd Congress of the International Society of Pediatric Oncology. Boston 2010. SIOP Education Book 2010:72–76
  15. Kalwinsky DK, Raimondi SC, Bunin NJ, Fairclough D, Pui CH, Relling MV, Ribeiro R, Rivera GK (1990) Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl 7:267–271
  16. Kanezaki R., Toki T., Terui K., Xu G., Wang R., Shimada A., Hama A., Kanegane H., Kawakami K., Endo M., Hasegawa D., Kogawa K., Adachi S., Ikeda Y., Iwamoto S., Taga T., Kosaka Y., Kojima S., Hayashi Y., Ito E., Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia, 10.1182/blood-2010-05-282426
  17. Kivivuori S. M., Rajantie J., Siimes M. A., Peripheral blood cell counts in infants with Down's syndrome, 10.1111/j.1399-0004.1996.tb04318.x
  18. Klusmann J.-H., Creutzig U., Zimmermann M., Dworzak M., Jorch N., Langebrake C., Pekrun A., Macakova-Reinhardt K., Reinhardt D., Treatment and prognostic impact of transient leukemia in neonates with Down syndrome, 10.1182/blood-2007-10-118810
  19. Kudo Kazuko, Kojima Seiji, Tabuchi Ken, Yabe Hiromasa, Tawa Akio, Imaizumi Masue, Hanada Ryoji, Hamamoto Kazuko, Kobayashi Ryoji, Morimoto Akira, Nakayama Hideki, Tsuchida Masahiro, Horibe Keizo, Kigasawa Hisato, Tsukimoto Ichiro, Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study Group, 10.1200/jco.2007.12.3687
  20. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group studies 2861 and 2891. Blood 91:608–615
  21. Malinge S., Izraeli S., Crispino J. D., Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome, 10.1182/blood-2008-11-163501
  22. Maloney K. W., Carroll W. L., Carroll A. J., Devidas M., Borowitz M. J., Martin P. L., Pullen J., Whitlock J. A., Willman C. L., Winick N. J., Camitta B. M., Hunger S. P., Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group, 10.1182/blood-2009-07-235291
  23. Massey G. V., A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481, 10.1182/blood-2005-06-2448
  24. Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster F R, Vormoor J, Maecker B, Sykora K W, Zintl F, Welte K, Sauer M, Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia, 10.1038/sj.bmt.1705844
  25. Mullighan Charles G, Collins-Underwood J Racquel, Phillips Letha A A, Loudin Michael G, Liu Wei, Zhang Jinghui, Ma Jing, Coustan-Smith Elaine, Harvey Richard C, Willman Cheryl L, Mikhail Fady M, Meyer Julia, Carroll Andrew J, Williams Richard T, Cheng Jinjun, Heerema Nyla A, Basso Giuseppe, Pession Andrea, Pui Ching-Hon, Raimondi Susana C, Hunger Stephen P, Downing James R, Carroll William L, Rabin Karen R, Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia, 10.1038/ng.469
  26. Muramatsu Hideki, Kato Koji, Watanabe Nobuhiro, Matsumoto Kimikazu, Nakamura Tomohiko, Horikoshi Yasuo, Mimaya Junichi, Suzuki Chizuko, Hayakawa Masahiro, Kojima Seiji, Risk factors for early death in neonates with Down syndrome and transient leukaemia : Poor Prognostic Factors in DS and TL, 10.1111/j.1365-2141.2008.07231.x
  27. Roll J. D., Reuther G. W., CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis, 10.1158/0008-5472.can-10-1528
  28. Rubin CM, Mick R, Johnson FL (1996) Bone marrow transplantation for the treatment of haematological disorders in Down’s syndrome: toxicity and outcome. Bone Marrow Transplant 18:533–540
  29. Tandonnet Julie, Clavel Jacqueline, Baruchel André, Nacka Fabienne, Pérel Yves, Myeloid leukaemia in children with down syndrome: Report of the registry-based French experience between 1990 and 2003, 10.1002/pbc.22515
  30. Tchernia Gil, Lejeune Francoise, Boccara Jean-Francoise, Denavit Marie-Francoise, Dommergues Jean-Paul, Bernaudin Francoise, Erythroblastic and/or Megakaryoblastic Leukemia in Down Syndrome : Treatment with Low-Dose Arabinosyl Cytosine, 10.1097/00043426-199602000-00011
  31. Tunstall-Pedoe O., Roy A., Karadimitris A., de la Fuente J., Fisk N. M., Bennett P., Norton A., Vyas P., Roberts I., Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations, 10.1182/blood-2008-04-152967
  32. Wechsler Joshua, Greene Marianne, McDevitt Michael A., Anastasi John, Karp Judith E., Le Beau Michelle M., Crispino John D., Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome, 10.1038/ng955
  33. Weijerman Michel E., de Winter J. Peter, Clinical practice : The care of children with Down syndrome, 10.1007/s00431-010-1253-0
  34. Whitlock J. A., Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study, 10.1182/blood-2003-10-3446
  35. Xavier Ana C, Ge Yubin, Taub Jeffrey, Unique clinical and biological features of leukemia in Down syndrome children, 10.1586/ehm.10.14
  36. Zwaan C. M., Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome, 10.1182/blood.v99.1.245
  37. Zwaan C. Michel, Reinhardt Dirk, Hitzler Johann, Vyas Paresh, Acute Leukemias in Children with Down Syndrome, 10.1016/j.hoc.2009.11.009
  38. Zwaan C. Michel, Reinhardt Dirk, Hitzler Johann, Vyas Paresh, Acute Leukemias in Children with Down Syndrome, 10.1016/j.pcl.2007.11.001